Shu‑Pin Huang

Prof/Dr. Shu-Pin Huang has received his PhD in Graduate of Medicine, Kaohsiung Medical University during the period of 1999 to 2004. Currently, he is working as Director of Graduate Institute of Clinical Medicine; Kaohsiung Medical University and Visiting Staff in Department of Urology, Kaohsiung Medical University Hospital in Taiwan. He is serving as a reviewer of several reputed journals like New England Journal of Medicine, Clinical Cancer Research, PLOS One, Cancer, Clinica Chimic Acta, Annals of Surgical Oncology, Journal of Endourology, International Journal of Oncology, Medicine, J Endourology, … etc. Prof Huang has published over 160 research articles in peer-review SCI journals. He is a member of Urological Association of Taiwan, American Urological Association (AUA) and European Association of Urology (EAU) and also served as Academic Editor for Medicine and Member of Editorial Board of International Journal of Urology. In additional to general Urology, Renal Transplantation and Robotic Surgery in Urology Oncology (majority on radical prostatectomy and Uro-oncology), Dr. Huang’s research interests were mainly focus on: Prostate Cancer, Molecular Epidemiology, Pharmacogenomic studies, Metabolic syndrome, Endocrine-Related Cancer, Urolithiasis, Andrology, Male Erectile dysfunction … etc.

15th August 2025

Time	Session

15:30 17:00	Free Paper 【Podium】 (12) Oncology Prostate (C) Chang Wook JeongKorea (Republic of) Moderator Extravasculare Renal Denervation to Treat Resistant HypertensionResistant hypertension is defined as uncontrolled blood pressure above the target, despite the concurrent use of three or more antihypertensive medications. Individuals with resistant hypertension are at a high risk for severe cardiovascular events and mortality. Managing resistant hypertension is challenging, and many non-pharmacological treatments, including renal denervation (RDN), have been introduced. This presentation will demonstrate the surgical technique of the extravascular RDN (eRDN) using the HyperQure™ System performed as part of the first-in-human trial. The surgeries were performed as a retroperitoneal approach in a modified prone position. The preliminary results will be presented, too. In the United States, a prospective, multicenter, early feasibility study is also underway. Paul Anthony L SungaPhilippines Moderator Shu‑Pin HuangTaiwan Moderator TICC - 4F Elegance Lounge

Time

Session

15:30

17:00

Free Paper 【Podium】 (12)

Oncology Prostate (C)

Chang Wook JeongKorea (Republic of) Moderator Extravasculare Renal Denervation to Treat Resistant HypertensionResistant hypertension is defined as uncontrolled blood pressure above the target, despite the concurrent use of three or more antihypertensive medications. Individuals with resistant hypertension are at a high risk for severe cardiovascular events and mortality. Managing resistant hypertension is challenging, and many non-pharmacological treatments, including renal denervation (RDN), have been introduced. This presentation will demonstrate the surgical technique of the extravascular RDN (eRDN) using the HyperQure™ System performed as part of the first-in-human trial. The surgeries were performed as a retroperitoneal approach in a modified prone position. The preliminary results will be presented, too. In the United States, a prospective, multicenter, early feasibility study is also underway.

Paul Anthony L SungaPhilippines Moderator

Shu‑Pin HuangTaiwan Moderator

TICC - 4F Elegance Lounge